130 related articles for article (PubMed ID: 34106032)
21. The evaluation of induction chemotherapy regimens for high-risk neuroblastoma in South African children
Van Heerden J; Geel J; Hendricks M; Wouters K; Büchner A; Naidu G; Hadley GP; Du Plessis J; Van Emmenes B; Van Zyl A; Vermeulen J; Kruger M
Pediatr Hematol Oncol; 2020 May; 37(4):300-313. PubMed ID: 32075464
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.
Du J; Yuan X
Eur J Pediatr; 2024 Jan; 183(1):185-202. PubMed ID: 37855927
[TBL] [Abstract][Full Text] [Related]
23. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
25. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma.
Sun Q; Chen Y; Jin Q; Yuan X
Eur J Pediatr; 2022 Dec; 181(12):4135-4147. PubMed ID: 36149505
[TBL] [Abstract][Full Text] [Related]
26. Clinical research on neuroblastoma based on serum lactate dehydrogenase.
Pang QM; Li K; Ma LJ; Sun RP
J Biol Regul Homeost Agents; 2015; 29(1):131-4. PubMed ID: 25864749
[TBL] [Abstract][Full Text] [Related]
27. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma.
Wibe E; Hannisdal E; Paus E; Aamdal S
Eur J Cancer; 1992; 28A(10):1692-5. PubMed ID: 1389487
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features of neuroblastoma: an analysis of 44 children].
Zhu CG; He XL; Tang ZG; Chen KK; Zou RY; Tian X; You YL
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Nov; 22(11):1193-1197. PubMed ID: 33172554
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factor in neuroblastoma.
Evans AE; D'Angio GJ; Propert K; Anderson J; Hann HW
Cancer; 1987 Jun; 59(11):1853-9. PubMed ID: 3567848
[TBL] [Abstract][Full Text] [Related]
30. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
[TBL] [Abstract][Full Text] [Related]
31. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
32. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
[TBL] [Abstract][Full Text] [Related]
33. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
35. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
37. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
38. Measurement of Serum Neuron-Specific Enolase in Neuroblastoma: Is There a Clinical Role?
Ferraro S; Braga F; Luksch R; Terenziani M; Caruso S; Panteghini M
Clin Chem; 2020 May; 66(5):667-675. PubMed ID: 32353141
[TBL] [Abstract][Full Text] [Related]
39. Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors.
Tsuchida Y; Honna T; Iwanaka T; Saeki M; Taguchi N; Kaneko T; Koide R; Tsunematsu Y; Shimizu K; Makino S
J Pediatr Surg; 1987 May; 22(5):419-24. PubMed ID: 3585664
[TBL] [Abstract][Full Text] [Related]
40. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.
Su Y; Wang L; Wang X; Yue Z; Xing T; Zhao W; Zhao Q; Duan C; Huang C; Han Y; Qiu L; Cheng X; Liu Y; Ma X
Cancer Med; 2019 Apr; 8(4):1558-1566. PubMed ID: 30793512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
